Replimune Group Inc (REPL NASDAQ) stock market data APIs
$9.8004
0.53(5.4%)
as of October 31, 2025
Try our APIs with
free plan!
Replimune Group Inc Financial Data Overview
Price chart is built with
Anychart
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Prev. Close
9.8004
Open
10.332
High
10.305
Low
9.6139
52 wk Range
2.68-17
Market Cap
801 M
Shares Outstanding
78 056 K
EPS
-0.95
Beta
0.421
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Replimune Group Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Replimune Group Inc data using free add-ons & libraries
Get Replimune Group Inc Fundamental Data
Replimune Group Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -287 160 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.8
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Replimune Group Inc News
New
Trending tickers: HSBC, Cleveland-Cliffs, GSI Technology, Beyond Meat and Replimune
Cleveland-Cliffs (CLF) Shares in Cleveland-Cliffs were lower in pre-market trading after closing 21% higher on Monday as the US steelmaker said it would increase efforts to develop its rare earth min...
Why Replimune Stock Was Soaring Today
Key Points The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. 10 stocks we like better than Replimune Group › Biote...
Noteworthy Monday Option Activity: UNH, REPL, CELC
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has...
Replimune soars 108% on BLA resubmission acceptance of melanoma asset
[Percentage Symbol with Slash Transforming into Upward Growth Graph Representing Financial Gains and Market Trends] J Studios * The US FDA has accepted Replimune's (NASDAQ:REPL [https://seekingalph...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
